SWGH.F Stock Overview
Together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Sawai Group Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥40.20 |
| 52 Week High | JP¥41.43 |
| 52 Week Low | JP¥38.18 |
| Beta | 0.20 |
| 11 Month Change | 0% |
| 3 Month Change | -2.97% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -26.72% |
| Change since IPO | 62.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| SWGH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -0.7% |
| 1Y | n/a | 20.6% | 32.5% |
Return vs Industry: Insufficient data to determine how SWGH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SWGH.F performed against the US Market.
Price Volatility
| SWGH.F volatility | |
|---|---|
| SWGH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SWGH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SWGH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 3,482 | Mitsuo Sawai | www.sawaigroup.holdings |
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States.
Sawai Group Holdings Co., Ltd. Fundamentals Summary
| SWGH.F fundamental statistics | |
|---|---|
| Market cap | US$1.79b |
| Earnings (TTM) | US$123.66m |
| Revenue (TTM) | US$1.17b |
14.4x
P/E Ratio1.5x
P/S RatioIs SWGH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SWGH.F income statement (TTM) | |
|---|---|
| Revenue | JP¥168.20b |
| Cost of Revenue | JP¥116.03b |
| Gross Profit | JP¥52.17b |
| Other Expenses | JP¥34.41b |
| Earnings | JP¥17.76b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | 426.75 |
| Gross Margin | 31.02% |
| Net Profit Margin | 10.56% |
| Debt/Equity Ratio | 41.4% |
How did SWGH.F perform over the long term?
See historical performance and comparison